Association of Comorbid Asthma and the Efficacy of Bioabsorbable Steroid-eluting Sinus Stents Implanted After Endoscopic Sinus Surgery in Patients with Chronic Rhinosinusitis with Nasal Polyps.
asthma
chronic rhinosinusitis
nasal polyps
outcome
steroid-eluting sinus stent
Journal
Current medical science
ISSN: 2523-899X
Titre abrégé: Curr Med Sci
Pays: China
ID NLM: 101729993
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
16
05
2023
accepted:
03
08
2023
medline:
1
11
2023
pubmed:
13
10
2023
entrez:
12
10
2023
Statut:
ppublish
Résumé
To identify factors affecting the efficacy of steroid-eluting sinus stents implanted after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). We performed a post-hoc analysis of a randomized self-controlled clinical trial on post-operative implantation of bioabsorbable steroid-eluting stents in patients with CRSwNP. Univariate logistic regression analysis was conducted to identify which of the following factors affect the response to post-operative stent implantation: sex, serum eosinophil levels, history of prior surgery, endoscopic scores, and comorbid conditions (asthma and allergic rhinitis). The primary outcome was the rate of post-operative intervention on day 30, and the secondary outcome was the rate of polypoid tissue formation (grades 2-3) on days 14, 30, and 90. A total of 151 patients with CRSwNP were included in the post-hoc analysis. Asthma was identified as the only risk factor for a poor response to steroid-eluting sinus stents on post-operative day 30, with an odds ratio of 23.71 (95% CI, 2.81, 200.16; P=0.004) for the need for post-operative intervention and 19 (95% CI, 2.20, 164.16; P=0.003) for moderate-to-severe polypoid tissue formation. In addition, the asthmatic group showed higher rates of post-operative intervention and polypoid tissue formation than the non-asthmatic group on post-operative day 30. Blood eosinophil levels were not identified as a risk factor for poor outcomes after stent implantation. Comorbid asthma, but not blood eosinophil level, impairs the efficacy of steroid-eluting sinus stents in the short term after ESS in patients with CRSwNP.
Identifiants
pubmed: 37828371
doi: 10.1007/s11596-023-2786-6
pii: 10.1007/s11596-023-2786-6
doi:
Substances chimiques
Steroids
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1005-1012Informations de copyright
© 2023. The Author(s).
Références
Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020,58(Suppl S29):1–464
pubmed: 32078669
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, 2019,394(10209):1638–1650
doi: 10.1016/S0140-6736(19)31881-1
pubmed: 31543428
Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021,9(10):1141–1153
doi: 10.1016/S2213-2600(21)00097-7
pubmed: 33872587
Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol, 2020,146(3):595–605
doi: 10.1016/j.jaci.2020.05.032
pubmed: 32524991
Wu AC, Fuhlbrigge AL, Robayo MA, et al. Cost-Effectiveness of Biologics for Allergic Diseases. J Allergy Clin Immunol Pract, 2021,9(3):1107–1117.e1102
doi: 10.1016/j.jaip.2020.10.009
pubmed: 33069886
Liu Z, Chen J, Cheng L, et al. Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis. Allergy Asthma Immunol Res, 2020,12(2):176–237
doi: 10.4168/aair.2020.12.2.176
pubmed: 32009319
pmcid: 6997287
Wormald PJ, Boustred RN, Le T, et al. A prospective single-blind randomized controlled study of use of hyaluronic acid nasal packs in patients after endoscopic sinus surgery. Am J Rhinol, 2006,20(1):7–10
doi: 10.1177/194589240602000102
pubmed: 16539287
Kennedy DW, Wright ED, Goldberg AN. Objective and subjective outcomes in surgery for chronic sinusitis. Laryngoscope, 2000,110(3 Pt 3):29–31
doi: 10.1097/00005537-200003002-00008
pubmed: 10718412
Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf, 2000,23(1):11–33
doi: 10.2165/00002018-200023010-00002
pubmed: 10915030
Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ, 2017,357:j1415
doi: 10.1136/bmj.j1415
pubmed: 28404617
pmcid: 6284230
Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol, 2011,1(1):23–32
doi: 10.1002/alr.20020
pubmed: 22287304
Luong A, Ow RA, Singh A, et al. Safety and Effectiveness of a Bioabsorbable Steroid-Releasing Implant for the Paranasal Sinus Ostia: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg, 2018,144(1):28–35
pubmed: 29098299
Kennedy DW. The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery. Expert Rev Respir Med, 2012,6(5):493–498
doi: 10.1586/ers.12.53
pubmed: 23134241
Huang Z, Zhou B, Wang D, et al. Comparison of Bioabsorbable Steroid-Eluting Sinus Stents Versus Nasopore After Endoscopic Sinus Surgery:A Multicenter, Randomized, Controlled, Single-Blinded Clinical Trial. Ear Nose Throat J, 2020,145561320947632
Forwith KD, Chandra RK, Yun PT, et al. ADVANCE: a multisite trial of bioabsorbable steroid-eluting sinus implants. Laryngoscope, 2011,121(11):2473–2480
doi: 10.1002/lary.22228
pubmed: 22020898
Goshtasbi K, Abouzari M, Abiri A, et al. Efficacy of steroid-eluting stents in management of chronic rhinosinusitis after endoscopic sinus surgery: updated meta-analysis. Int Forum Allergy Rhinol, 2019,9(12):1443–1450
doi: 10.1002/alr.22443
pubmed: 31539461
pmcid: 6901756
Hong H, Wang D, Tan KS, et al. Sinus computed tomography predicts clinical response to corticosteroids in chronic rhinosinusitis with nasal polyps. Clin Transl Allergy, 2018,8:24
doi: 10.1186/s13601-018-0211-1
pubmed: 29988550
pmcid: 6027579
Epperson MV, Phillips KM, Caradonna DS, et al. Predictors of efficacy for combination oral and topical corticosteroids to treat patients with chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol, 2019,9(12):1436–1442
doi: 10.1002/alr.22431
pubmed: 31609091
Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J, 2015,46(3):622–639
doi: 10.1183/13993003.00853-2015
pubmed: 26206872
pmcid: 4554554
Hu Y, Cao PP, Liang GT, et al. Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults. Laryngoscope, 2012,122(3):498–503
doi: 10.1002/lary.22507
pubmed: 22252861
Tajudeen BA, Ganti A, Kuhar HN, et al. The presence of eosinophil aggregates correlates with increased postoperative prednisone requirement. Laryngoscope, 2019,129(4):794–799
doi: 10.1002/lary.27693
pubmed: 30593672
Xu G, Jiang H, Li H, et al. Stages of nasal mucosal transitional course after functional endoscopic sinus surgery and their clinical indications. ORL J Otorhinolaryngol Relat Spec, 2008,70(2):118–123
doi: 10.1159/000114535
pubmed: 18408410
Gurrola J2nd, Borish L. Chronic rhinosinusitis: Endotypes, biomarkers, and treatment response. J Allergy Clin Immunol, 2017,140(6):1499–1508
doi: 10.1016/j.jaci.2017.10.006
pubmed: 29106996
Sella GCP, Tamashiro E, Sella JA, et al. Asthma Is the Dominant Factor for Recurrence in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract, 2020,8 (1):302–309
doi: 10.1016/j.jaip.2019.08.007
pubmed: 31425833
Bai J, Huang JH, Price CPE, et al. Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol, 2022,150(2):352–361.e357
doi: 10.1016/j.jaci.2022.02.029
pubmed: 35305978
pmcid: 9378510
Liao B, Liu JX, Li ZY, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy, 2018,73(7):1459–1469
doi: 10.1111/all.13411
pubmed: 29331025
Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol, 2016,137(5):1449–1456.e1444
doi: 10.1016/j.jaci.2015.12.1324
pubmed: 26949058
Laidlaw TM, Mullol J, Woessner KM, et al. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract, 2021,9(3):1133–1141
doi: 10.1016/j.jaip.2020.09.063
pubmed: 33065369
de Borja Callejas F, Martínez-Antón A, Picado C, et al. Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps. Laryngoscope, 2015,125(5):E158–E167
doi: 10.1002/lary.25147
pubmed: 25641502
Jin M, Watkins S, Larriba Y, et al. Real-time imaging of asthmatic epithelial cells identifies migratory deficiencies under type-2 conditions. J Allergy Clin Immunol, 2022,149(2):579–588
doi: 10.1016/j.jaci.2021.08.027
pubmed: 34547368
Zeng M, Wang H, Liao B, et al. Clinical and Biological Markers Predict the Efficacy of Glucocorticoid- and Macrolide-Based Postoperative Therapy in Patients With Chronic Rhinosinusitis. Am J Rhinol Allergy, 2021,35(5):596–606
doi: 10.1177/1945892420982236
pubmed: 33348995
Vento SI, Blomgren K, Hytönen M, et al. Prevention of relapses of nasal polyposis with intranasal triamcinolone acetonide after polyp surgery: a prospective double-blind, placebo-controlled, randomised study with a 9-month follow-up. Clin Otolaryngol, 2012,37(2):117–123
doi: 10.1111/j.1749-4486.2012.02455.x
pubmed: 22329774
De Corso E, Settimi S, Tricarico L, et al. Predictors of Disease Control After Endoscopic Sinus Surgery Plus Long-Term Local Corticosteroids in CRSwNP. Am J Rhinol Allergy, 2021,35(1):77–85
doi: 10.1177/1945892420936196
pubmed: 32564684
Mukherjee M, Svenningsen S, Nair P. Glucocortiosteroid subsensitivity and asthma severity. Curr Opin Pulm Med, 2017,23(1):78–88
doi: 10.1097/MCP.0000000000000337
pubmed: 27801710
Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol, 2015,15(1):57–65
doi: 10.1038/nri3786
pubmed: 25534623
pmcid: 4390063
Fan Y, Chen S, Qu X, et al. A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China. J Allergy Clin Immunol, 2011,127(2):520–522.e521–e525
doi: 10.1016/j.jaci.2010.09.023